The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...

Listen to Vladimir Putin, and one would think Russia is marching to victory in Ukraine and overcoming whatever minor economic challenges it faces, thanks to the support of its patriotic people. On ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

This transcript was created using speech recognition software. While it has been reviewed by human transcribers, it may contain errors. Please review the episode audio before quoting from this ...

It was dark and silent, with a chill in the air, as an army of police vehicles blue-lighted their way through the city, headed for one destination. If you told me at 6.20am that Merseyside Police were ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer discussed, along with the tech battleground. Answering a caller’s query about the stock during the lightning round, Cramer ...

Hero who wrestled gun from terrorist says he’d do it again despite being riddled with bullets WA government meets with Jewish leaders after Bondi Beach terror ...

Investors are betting that there are higher bids yet to come for Warner Bros. Paramount Chief Executive Officer David Ellison sat with a number of Warner investors in meetings in New York on Tuesday, ...